The role of baseline glucocorticosteroid therapy in forming metabolic disorders in patients with bronchial asthma

The aim of the investigation is to study the incidence and clinical features of metabolic syndrome in patients with bronchial asthma (BA) in various ways of performing baseline therapy of glucocorticosteroids (GCS). Materials and Methods. There have been examined 116 patients with medium and severe BA. The patients have been divided into three groups: the 1st group - 39 patients, who have not received baseline therapy; the 2nd group - 51 patients, who have taken medium and high doses of inhalation GCS for 2 years; the 3rd group - 26 patients, who have taken systemic GCS for 2 years. Conclusion. BA is frequently associated with metabolic disorders. The rate and degree of manifestation of these disorders increase significantly against the background of GCS therapy. Visceral obesity, arterial hypertension, dyslipidemia and abnormalities of carbohydrate metabolism are the most common among other manifestations of metabolic syndrome in BA patients. Baseline therapy of inhalation GCS has its metabolic consequences including obesity, hyperinsulinemia, as well as insulin resistance development.